Top Markets
Coin of the day
Mercury Biopharmaceutical Corporation Mercury Biopharmaceutical Corporation

Mercury Biopharmaceutical Corporation

6932
株式のランク #23452
Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury... Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury Biopharmaceutical Corporation is dedicated to creating innovative pharmaceutical solutions for medical conditions currently lacking adequate treatment options. A cornerstone of their strategy is the proprietary StackDose platform, an advanced drug development system designed to formulate novel medication delivery methods. This platform facilitates precisely timed drug release, targeted absorption at specific locations within the body, and flexible dosage modifications. The primary objective of StackDose is to significantly boost the bioavailability of active pharmaceutical ingredients, leading to a reduction in required drug dosages and fewer adverse effects. Their development pipeline currently addresses a variety of ailments, such as erectile dysfunction, pulmonary hypertension, sleep disturbances, benign prostatic hyperplasia, angina, migraines, hypertension, and pain management.
株価
$0.17616661
最終同期: 2026-08-21
時価総額
$73.48M
変化(1日)
0.18%
変化(1年)
-37.76%
TW
取引 Mercury Biopharmaceutical Corporation (6932)

カテゴリー

Mercury Biopharmaceutical Corporation(6932)の収益
Aug 2026 時点の収益 TTM: 0
Mercury Biopharmaceutical Corporation の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Mercury Biopharmaceutical Corporation の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。